What is Bio-Techne's market cap?

Bio-Techne (TECH) has a market capitalization of $11.2B and trades on NASDAQ.

What is Bio-Techne's revenue and profitability?

Bio-Techne generated $1.2B in trailing twelve-month revenue with net income of $149.8M, representing a net margin of 10.9%. Gross margin stands at 65.0%, with free cash flow of $269.6M. These figures are based on the Q1 2026 filing.

Who are Bio-Techne's competitors?

Bio-Techne's key competitors include Danaher Corporation, Thermo Fisher Scientific, 10x Genomics, and others. These companies compete in similar markets and product categories.

Who does Bio-Techne partner with?

Bio-Techne's notable partners include Spear Bio, Wilson Wolf Corporation.

What subsidiaries does Bio-Techne have?

Bio-Techne's subsidiaries include Research and Diagnostic Systems, Inc., Lunaphore SA.

Where is Bio-Techne headquartered?

Bio-Techne is headquartered in United States of America and employs approximately 3,050 people. It has been publicly traded since 1989.

Bio-Techne

TECH

Bio-Techne is a global life sciences company that develops and manufactures high-quality reagents, instruments, and services for the research, diagnostics, and bioprocessing markets.

Market cap

$11.16B+23.3%

Revenue$1.2B+0.2%

Net income$149.8M-5.3%

Free cash flow$269.6M+22.1%

EPS (diluted)$0.94-6.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q3 2026 report

May 6, 2026

Revenue$311.4MMiss by $4.7M EPS$0.53Miss by $0.02

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$314.7M

EPS estimate$0.52

Financials

Q3 2026

Income statement

See full

Revenue$311.4M-1.5%

Gross profit$208.3M-2.9%

Operating income$75.5M+95.0%

Net income$51.0M+126%

EPS (diluted)$0.32+129%

Balance sheet

See full

Cash & equivalents$209.8M+49.2%

Total debt$290.3M-31.4%

Total equity$2.1B+3.3%

Total assets$2.6B-3.5%

Cash flow

See full

Operating cash flow$86.7M+111%

CapEx$9.1M-10.2%

Free cash flow$77.6M+150%

Valuation & ratios

Valuation

See full

Market cap$11.16B+23.3%

Enterprise value$11.24B+18.8%

P/E74.5×—

P/S9.2×+1.7×

Profitability

See full

Gross margin65%-0.8pp

FCF margin22.3%+4.0pp

Returns & leverage

See full

Debt / equity0.1×-0.1×

Current ratio4.5×+0.8×

Segments

By product

See full

Consumables$257.3M-0.2%

Instruments$27.7M+5.9%

Service$21.4M-21.3%

Royalty$5.0M-1.4%

By segment

See full

Protein Sciences$226.2M-0.7%

Diagnostics And Spatial Biology$85.6M-4.1%

Competitors

By market cap

Thermo Fisher Scientific$207.93B+13.6%

Danaher$138.14B-4.9%

Agilent Technologies$38.9B+14.7%

Revvity$12.1B+7.6%

TEC

Bio-Techne$11.2B+21.6%

Bio-Rad Laboratories$8.5B+22.9%

10x Genomics, Inc.$5.8B+223%

Standard BioTools Inc.$303.2M-40.9%

By revenue growth

Agilent Technologies+9.1%

Thermo Fisher Scientific+5.6%

Revvity+4.8%

Danaher+4.6%

10x Genomics, Inc.+2.3%

Bio-Rad Laboratories+1.9%

TEC

Bio-Techne+0.2%

By net margin

Agilent Technologies19.55%+2.0pp

Danaher15.95%+1.7pp

Thermo Fisher Scientific15.19%0.0pp

TEC

Bio-Techne10.89%-0.7pp

Revvity8.26%-2.1pp

Bio-Rad Laboratories6.52%+91.7pp

10x Genomics, Inc.-3.55%+21.6pp

Profile

Bio-Techne is a global life sciences company that develops and manufactures high-quality reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. The company provides essential tools for investigating biological processes, drug discovery, and clinical diagnostics, positioning itself as a primary provider of biological content for the scientific community.

Competitive position

A leading developer of high-quality biological reagents and proteomic tools with a strategy focused on being first-to-market with biological content.

GeographiesNorth America, Europe, Asia, United Kingdom, Canada, Switzerland, China

Customer segmentsAcademic research institutions, Pharmaceutical companies, Biotechnology companies, Clinical laboratories

Business modelManufacturing, Direct-to-customer sales, B2B product sales

SuppliersRaw material suppliers, Specialized chemical providers, Laboratory equipment components

CustomersAcademic researchers, Drug discovery teams, Clinical diagnostic providers, Bioprocessing manufacturers

CountryUnited States of America

Listed1989

Employees3.1K

CEOKim Kelderman

SectorHealthcare

IndustryBiotechnology

Websitebio-techne.com

FilingsSEC EDGAR

Ask your AI about Bio-Techne.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bio-Techne's market cap?: Bio-Techne (TECH) has a market capitalization of $11.2B and trades on NASDAQ.
What is Bio-Techne's revenue and profitability?: Bio-Techne generated $1.2B in trailing twelve-month revenue with net income of $149.8M, representing a net margin of 10.9%. Gross margin stands at 65.0%, with free cash flow of $269.6M. These figures are based on the Q1 2026 filing.
Who are Bio-Techne's competitors?: Bio-Techne's key competitors include Danaher Corporation, Thermo Fisher Scientific, 10x Genomics, and others. These companies compete in similar markets and product categories.
Who does Bio-Techne partner with?: Bio-Techne's notable partners include Spear Bio, Wilson Wolf Corporation.
What subsidiaries does Bio-Techne have?: Bio-Techne's subsidiaries include Research and Diagnostic Systems, Inc., Lunaphore SA.
Where is Bio-Techne headquartered?: Bio-Techne is headquartered in United States of America and employs approximately 3,050 people. It has been publicly traded since 1989.